EX-23.2 3 tm2132065d1_ex23-2.htm EXHIBIT 23.2

 

Exhibit 23.2

 

Consent of Independent Registered Public Accounting Firm

 

We consent to the use of our report dated March 11, 2021, with respect to the consolidated financial statements of Nabriva Therapeutics plc, incorporated herein by reference.

 

/s/ KPMG LLP  
   
Philadelphia, Pennsylvania  
November 9, 2021